EFFECT OF CO-ENZYME Q1O ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE-2 DIABETES MELLITUS

India has nearly 33 million diabetic subjects today, Prediabetes conditions like impaired glucose tolerance and impaired fasting glucose are also on the rise, indicating the possibility of further rise in the prevalence of diabetes. This study was conducted in Department of Pharmacology and Department of Medicine Bharath Institute of Higher Education and Research, Chennai, Tamilnadu during the period of August 2015 - February 2016 (6months). All the subjects were between the ages of 18-65 years. 40 subjects were selected for the study and their fasting blood glucose, blood HbA1c level, lipid profile (LDL, Triglycerides, HDL, TC), blood coenzyme Q10 level, BMI were analyzed at the beginning of the study, 12th week and 24th week. Adverse events were also noted in each visit to meet the peoples. The study showed, the Metformin with Coenzyme Q1O group, reduction in fasting blood glucose along with HbAlc level at the end of treatment period. In conclusion, coenzyme QlO along with Metformin was well-tolerated by patients with type 2 Diabetes Mell it us. With more advanced therapy for Diabetes evolving, this therapy with biguanide and coenzyme QlO, assures effective in long-term glycemic control and can provide additional benefits not only in Diabetes but as antioxidant in other diseases too.